Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2004 3
2005 6
2006 11
2007 19
2008 16
2009 8
2010 10
2011 10
2012 11
2013 9
2014 7
2015 22
2016 18
2017 22
2018 24
2019 19
2020 26
2021 30
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

218 results
Results by year
Filters applied: . Clear all
Page 1
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Abou-Alfa GK, et al. Among authors: ryoo by. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. N Engl J Med. 2018. PMID: 29972759 Free PMC article. Clinical Trial.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Finn RS, et al. Among authors: ryoo by. J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2. J Clin Oncol. 2020. PMID: 31790344 Clinical Trial.
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. Kelley RK, et al. Among authors: ryoo by. ESMO Open. 2020 Aug;5(4):e000714. doi: 10.1136/esmoopen-2020-000714. ESMO Open. 2020. PMID: 32847838 Free PMC article. Clinical Trial.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Zhu AX, et al. Among authors: ryoo by. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Lancet Oncol. 2015. PMID: 26095784 Clinical Trial.
Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J, Yoon SM, Park JH, Seo DW, Lee SS, Kim MH, Lee SK, Park DH, Song TJ, Ryoo BY, Chang HM, Kim KP, Yoo C, Jeong JH, Kim SC, Hwang DW, Lee JH, Song KB, Jo YY, Park J, Kim JH. Jung J, et al. Among authors: ryoo by. PLoS One. 2019 Apr 12;14(4):e0214970. doi: 10.1371/journal.pone.0214970. eCollection 2019. PLoS One. 2019. PMID: 30978229 Free PMC article.
218 results